Abstract: An antibody capable of specifically binding to GUCY2C or an antigen-binding fragment thereof. The antibody or the antigen-binding fragment thereof can specifically bind to GUCY2C with high affinity, and can be taken as a drug to treat gastrointestinal malignancies.

Abstract: A CD19 antibody and an application thereof, an antibody or antigen binding fragment specifically binding to human CD19, a multi-characteristic antigen binding molecule, a chimeric antigen receptor, an immune effector cell, a nucleic acid molecule, a vector, a cell, a preparation method, a pharmaceutical composition, a pharmaceutical use, and a disease treatment method. The present invention has great significance for the development of drugs for treating CD19-related diseases.

Abstract: An antibody, or an antigen-binding fragment of same, specifically binding to a BCMA, a nucleic acid encoding same, an expression vector and an expression cell thereof, a preparation method therefor, a pharmaceutical composition thereof, and the use thereof in treating a disease, for example, the use thereof in treating a tumour.

Abstract: Disclosed is an IL-15 mutant fusion protein preparation. Specifically, provided is an IL-15 mutant fusion protein pharmaceutical composition. The composition comprises an IL-15 mutant fusion protein, a buffer solution, a protein stabilizer and a surfactant. The pharmaceutical composition can maintain the stability of the IL-15 mutant fusion protein in the long-term storage and transportation process of the product, and thus, the stability, safety and effectiveness of the drug are ensured.

Abstract: The present disclosure relates to a bispecific antibody capable of specifically binding PVRIG and TIGIT, which can modulate the function of immune cells and can be used as a drug to treat diseases related to immune abnormalities, such as tumors.

Abstract: The present invention relates to a CD16 antibody and the use thereof. Specifically, disclosed are an antibody or an antigen-binding fragment specifically binding CD16, and an encoding nucleic acid, an expression vector and an expression cell thereof, a preparation method therefor, a pharmaceutical composition thereof, and the use thereof for treating diseases, such as the use thereof in the treatment of tumors. The CD16 antibody holds great significance for the development of a CD16 antibody therapeutic drug and a CD16 detection reagent.

Abstract: A compound as represented by formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof, a preparation method therefor, and the use thereof in the treatment of tumors, inflammatory diseases or autoimmune diseases.

Abstract: The present disclosure discloses IL-2 mutants and uses thereof. More specifically, the disclosure provides IL-2 mutants and corresponding fusion proteins, conjugates, nucleic acid fragments, vectors, host cells, methods for preparing the mutants or fusion proteins, IL-2 mutants or fusion proteins prepared according to the methods, pharmaceutical compositions, pharmaceutical uses, methods for treating diseases, and methods for preferentially stimulating regulatory T cells. Compared to wild-type IL-2, the IL-2 mutants of the present disclosure have higher Tm values and improved stability; alternatively, the IL-2 mutants of the present disclosure have an increased yield or changed binding activity to the IL-2R?? complexes compared to wild-type IL-2.

Abstract: The present disclosure discloses IL-2 mutants and uses thereof. More specifically, the disclosure provides IL-2 mutants and corresponding fusion proteins, conjugates, nucleic acid fragments, vectors, host cells, methods for preparing the mutants or fusion proteins, IL-2 mutants or fusion proteins prepared according to the methods, pharmaceutical compositions, pharmaceutical uses, methods for treating diseases, and methods for preferentially stimulating regulatory T cells. Compared to wild-type IL-2, the IL-2 mutants of the present disclosure have higher Tm values and improved stability; alternatively, the IL-2 mutants of the present disclosure have an increased yield or changed binding activity to the IL-2R?? complexes compared to wild-type IL-2.

Abstract: The compound as shown in formula (I) or a pharmaceutically acceptable salt or pharmaceutical composition thereof, and a preparation method therefor, and the use thereof as an MAT2A inhibitor. Ring A, ring Q, X, Y, X1, X2, L and R1 in formula (I) are as defined in the description.

Abstract: The present invention relates to a single-domain antibody against MSLN (mesothelin) and a preparation method therefor and an application thereof. The MSLN antibody has high affinity for MSLN, and therefore can be applied to the preparation of a medicament for treating tumors, etc.

Abstract: An anti-CD33 antibody and a preparation method therefor and an application thereof. The anti-CD33 antibody has high affinity with CD33 protein, and therefore, can be used for preparation of a drug for treating tumor and the like.

Abstract: Disclosed in the present invention are a humanized antibody that can specifically bind to TNFR2, or an antigen-binding fragment thereof. The humanized antibody or antigen-binding fragment thereof can regulate the function of immune cells and can be used in a drug for treating diseases related to immune abnormalities, such as tumours.

Abstract: An EGFR nanobody, and a preparation method therefor and the use thereof. The EGFR nanobody has high affinity for a wild-type EGRF protein, and also recognizes the EGRFvIII protein.

Abstract: CD22 antibodies, a preparation method therefor, and an application thereof. The CD22 antibodies have a high affinity to CD22 protein Therefore, the CD22 antibodies can be used in the preparation of drugs for the treatment of diseases such as tumors and autoimmune diseases.

Abstract: An antibody or antigen-binding fragment specifically binding to HER2, a multi-specific antigen binding molecule, a chimeric antigen receptor, an immune effector cell, a nucleic acid fragment, a vector, a host cell, a pharmaceutical composition, a kit, a preparation method, and an application thereof in treatment of tumors or cancers and detection of HER2, which is of great significance for the development of HER2 antibody therapeutic drugs and detection reagents.

Abstract: Provided are a GPC3 antibody and an application thereof, and specifically provided are an antibody or an antigen-binding fragment that specifically binds to GPC3, a multispecific antigen-binding molecule, a chimeric antigen receptor, an immune effector cell, isolated nucleic acid fragments, a vector, a host cell, a corresponding preparation method, a pharmaceutical composition, a treatment method, a pharmaceutical use, a GPC3 detection method and a detection kit. The present disclosure is of great significance in the preparation of drugs for treating cancer or tumor.

Abstract: Use of a composition in preparation of a drug for treating a patient suffering from a cerebral stroke. The composition includes edaravone and dexborneol, and the patient has a history of hypertension.

Abstract: Provided are an CD22 nano antibody, and a preparation method therefor and an application thereof. The CD22 nano antibody has high affinity with a CD22 protein, and can be used for preparing drugs for treating tumors, autoimmune diseases, etc.

Abstract: A stable pharmaceutical composition contains active ingredients of edaravone and dextrocamphol can control the content of unique impurity SCR-756 and impurity SCR-757 thereof.